ClinicalTrials.gg
Active, not recruitingNCT04476901DCMIIUpdated Sep 29, 2026

Administration of Allogeneic-MSC in Patients With Non-Ischemic Dilated Cardiomyopathy

A Phase 2 interventional study of allogeneic human mesenchymal stem cells (hMSCs) and Placebo in Non-ischemic Dilated Cardiomyopathy, sponsored by Joshua M Hare. Active, not recruiting at 4 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by Joshua M Hare · Phase 2, Interventional, and Treatment

How we know

Updated Sep 29, 2026Now Active, not recruitingEnrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
107
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 64 studies in Cardiomyopathy, Dilated with a site in United States — 14 open to participants now, 20 under way, 2 of them phase 3. Cardiomyopathy, Dilated · United States.

Enrollment
10th of 42
107 · median 37
Started
2021
with 2 others
Phase 2
8 of 64
none open now
Primary completion
2027-04
later than 4 of 19 live
Registered
47th of 64
by date
Lead sponsor
2 of 64
Joshua M Hare

Among the 64 studies in Cardiomyopathy, Dilated with a site in United States, this one is the 10th largest by enrollment of the 42 interventional ones that give a count, is one of 3 that started in 2021, is one of 8 in phase 2, reaches primary completion later than 4 of the 19 other live ones, and was the 47th registered.

Cardiomyopathy, Dilated

256 studies on the registry are indexed under Cardiomyopathy, Dilated; 67 are open to participants now.

Browse Cardiomyopathy, Dilated studies →

Open to participants now

14 of the 64 studies in Cardiomyopathy, Dilated with a site in United States are open now. Recruiting first, the newest first:

9 more — sign in →

All 14 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 54 Cardiomyopathy, Dilated studies recruiting now, 31 (57%) set no upper age limit and 15 (28%) stop at 75 or younger; 14 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies in Cardiomyopathy, Dilated with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and effectiveness of an experimental drug called human allogeneic mesenchymal stem cell therapy.

03

Conditions studied

  • Non-ischemic Dilated Cardiomyopathy

Keywords

  • Allogeneic mesenchymal stem cells
  • Bone marrow-derived mesenchymal stem cells
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

In order to be eligible to participate in this study, an individual must meet all of the following criteria:

  1. Men and women aged 18 to 80 years (inclusive) at the time of signing the form.
  2. Diagnosis of NIDCM with ≤45%.
  3. Appropriate guideline-directed optimal medical therapy for non-ischemic cardiomyopathy. At a minimum, subjects must be on beta blockers and angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) or Angiotensin Receptor Neprilysin Inhibitors (ARNI) or have appropriate medical indication precluding use of one or both of these agents. Subjects must be on a stable regimen for at least 30 days prior to the procedure. Dose titration is allowed.
  4. Be a candidate for cardiac catheterization*
  5. Be willing to undergo DNA test.

Exclusion criteria

Exclusion Criteria:

An individual who meets any of the following criteria will be excluded from participation in this study:

  1. Be eligible for or require standard-of-care surgical or percutaneous intervention for the treatment of non-ischemic dilated cardiomyopathy
  2. Clinical manifestation of coronary artery disease (CAD) (e.g., chest pain and concomitant clinical findings such as changes suggestive of coronary ischemia, myocardial infarction) or evidence of endocardial or transmural scar on cardiac MRI suggestive of undiagnosed CAD or history of percutaneous coronary intervention (PCI) or coronary artery bypass surgery (CABG). Be indicated for or require coronary artery revascularization
  3. Documented presence of epicardial stenosis of 70% or greater in one or more major epicardial coronary arteries
  4. Valvular heart disease including 1) aortic valve prosthesis, mechanical mitral valve, and mitral valve clip; 2) severe aortic valve insufficiency/regurgitation within 12 months of consent*
  5. Aortic stenosis with valve area ≤ 1.5cm2*
  6. Cardiomyopathy due to acute Post-partum (within 6 months), Non-compaction*, or Hypertrophic* cardiomyopathy
  7. Cardiomyopathy due to known toxin (e.g amyloid) Note: anthracycline induced cardiomyopathy will be allowed
  8. > 550 ms on baseline electrocardiogram (ECG) (note: QTc interval is the interval between the start of the Q wave and the end of the T wave in the heart's electrical cycle)
  9. Automated Implantable Cardioverter Defibrillator (AICD) appropriate firing or anti tachycardia pacing for ventricular tachycardia or ventricular fibrillation within 30 days prior to consent
  10. Have an estimated baseline below the clinical site's institutional cutoff
  11. A hematologic abnormality during baseline testing as evidenced by \< 9 g/dl; hematocrit \< 30%; \< 2,000 or total WBC count more than 2 times ; or values \< 100,000/ul
  12. Have liver dysfunction, as evidenced by enzymes Enzyme (AST) and Alanine Aminotransferase Enzyme (ALT) greater than three times the ULN
  13. Have a bleeding diathesis or coagulopathy ( (INR) > 1.5), cannot be withdrawn from anticoagulation therapy, or will refuse blood transfusions
  14. Be a solid organ transplant recipient. This does not include prior cell based therapy (>12 months prior to enrollment), bone, skin, ligament, tendon or corneal grafting.
  15. Have a history of organ or cell transplant rejection
  16. Have a clinical history of within the past 12 months (i.e., subjects with prior malignancy must be disease free for 12 months), except curatively treated basal cell or squamous cell carcinoma or cervical carcinoma
  17. Drug and/or alcohol abuse or dependence within the past 9 months
  18. Be serum positive for , surface antigen, or viremic
  19. Documented presence of a known Left Ventricular (LV) thrombus, aortic dissection, or aortic aneurysm. (Refer to "Guidance to the PI" section with regards to LV thrombus, below)*
  20. Blood glucose levels () >10%
  21. Severe radiographic contrast allergy
  22. Known history of anaphylactic reaction to penicillin or streptomycin
  23. to dimethyl sulfoxide (DMSO)
  24. Non-cardiac condition with \< 1 year
  25. Acute stroke or within 3 months of enrollment
  26. Be pregnant, nursing, or of while not practicing effective methods
  27. Pacemaker-dependence with an Implantable Cardioverter Defibrillator (ICD) (Note: pacemaker-dependent candidates without an ICD are not excluded)
  28. Presence of a pacemaker and/or ICD generator with any of the following limitations/conditions:

    • manufactured before the year 2000
    • leads implanted \< 6 weeks prior to consent
    • non-transvenous epicardial or abandoned leads
    • subcutaneous ICDs
    • leadless pacemakers
  29. A cardiac resynchronization therapy (CRT) device implanted less than 3 months prior to consent
  30. Other MRI (e.g. subject body habitus incompatible with MRI)
  31. Need for advanced heart failure therapy (e.g. IV inotropes)
  32. Be currently participating (or participated within the previous 30 days) in an therapeutic or device trial
  33. Any other condition that in the judgment of the Investigator would be a contraindication to enrollment or follow-up

(*) Applies to subjects receiving product via transendocardial administration only

Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
107 participants (actual)

Study arms

  • Placebo comparator
    Genotype A administered with placebo Group

    Participants whose blood genotyping resulted with Genotype A (absence of any variant/ presence of benign variant) and randomized to the placebo group will receive the placebo intervention.

    Other: Placebo

  • Experimental
    Genotype A administered with hMSC Group

    Participants whose blood genotyping resulted with Genotype A (absence of any variant/ presence of benign variant) and randomized to the treatment group will receive the hMSC intervention.

    Biological: allogeneic human mesenchymal stem cells (hMSCs)

  • Placebo comparator
    Genotype B administered with placebo Group

    Participants whose blood genotyping resulted with Genotype B (variants of uncertain significance) and randomized to the placebo group will receive the placebo intervention.

    Other: Placebo

  • Experimental
    Genotype B administered with hMSC Group

    Participants whose blood genotyping resulted with Genotype B (variants of uncertain significance) and randomized to the treatment group will receive the hMSC intervention.

    Biological: allogeneic human mesenchymal stem cells (hMSCs)

  • Placebo comparator
    Genotype C administered with placebo Group

    Participants whose blood genotyping resulted with Genotype C (pathogenic or likely pathogenic variants) and randomized to the placebo group will receive the placebo intervention.

    Other: Placebo

  • Experimental
    Genotype C administered with hMSC Group

    Participants whose blood genotyping resulted with Genotype C (pathogenic or likely pathogenic variants) and randomized to the treatment group will receive the hMSC intervention.

    Biological: allogeneic human mesenchymal stem cells (hMSCs)

Interventions

  • Biologicalallogeneic human mesenchymal stem cells (hMSCs)

    allo-hMSCs, 16-20 million cells/ml delivered at a dose of 0.5 ml/ injection x 10 injections for a total of 80-100 million allo-hMSCs or a single administration of intravenous allogeneic hMSCs (100 million).

  • OtherPlacebo

    Placebo will be administered as injections of plasmalyte A supplemented with 1% of 25% human serum albumin (HSA). 0.5 ml/ injection x 10 injections or an intravenous placebo infusion of Cell-free PlasmaLyte-A medium supplemented with 1% of 25% human serum albumin (HSA)

06

What researchers measure

Primary outcomes

  1. Change in LVEF

    Change in Left Ventricular Ejection Fraction (LVEF) as assessed via cardiac Magnetic Resonance Imaging (MRI)

    Time frame: Baseline, 12 months

Secondary outcomes

  1. Change in global ventricular strain

    Change in global ventricular strain as assessed via cardiac Harmonic Phase (HARP) MRI

    Time frame: Baseline, 12 months

  2. Change in left regional strain

    Change in regional ventricular strain as assessed via cardiac HARP MRI

    Time frame: Baseline, 12 months

  3. Left ventricular function concordance

    The left ventricular function concordance will be measured as the Number of individuals who experienced an increase in left ventricular ejection fraction (LVEF) and a simultaneous decrease in both left ventricular end systolic volume index (LVESVI) and left ventricular end diastolic volume index (LVEDVI)

    Time frame: 12 months

  4. Change in LVEDVI

    Change in left ventricular end diastolic index (LVEDVI) as assessed via cardiac MRI

    Time frame: Baseline, 12 months

  5. Change in LVESVI

    Change in left ventricular end systolic index (LVESVI) as assessed via cardiac MRI

    Time frame: Baseline, 12 months

  6. Change in Maximal oxygen consumption (peak VO2)

    Change in maximal oxygen consumption (peak VO2) as assessed via treadmill

    Time frame: Baseline, 12 months

  7. Change in Exercise tolerance

    Change in exercise tolerance as assessed as the distance covered via the six-minute walk test

    Time frame: Baseline, 12 months

  8. Change in Minnesota Living with Heart Failure Questionnaire (MLHFQ) Score

    Minnesota Living with Heart Failure Questionnaire (MLHFQ) is a 21-item questionnaire with a total score ranging from 0 to 105 with lower scores indicative of better outcome.

    Time frame: Baseline, 12 months

  9. Change in New York Heart Association (NYHA) Class

    NYHA Classifications of heart failure are as follows: Class I (no limitations); Class II (mild symptoms); Class III (marked limitations); Class IV (Severe limitations)

    Time frame: Baseline, 12 months

  10. Percent change in flow mediated diameter

    Change in endothelial function will be reported as the percent change in flow mediated diameter assessed via flow mediated dilation (FMD).

    Time frame: Baseline, 12 months

  11. Change in EPC-CFU

    Change in endothelial function will be reported as the change in Endothelial Progenitor Cell Colony Forming Unit (EPC-CFU) assessed via blood sample assay

    Time frame: Baseline, 12 months

  12. Change in N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP)

    Change in NT-proBNP as assessed via blood draw

    Time frame: Baseline, 12 months

  13. Incidence of MACE

    Safety will be reported as the incidence of Major Adverse Cardiac Events (MACE) assessed by treating physician

    Time frame: 12 months

  14. Incidence of TE-SAEs

    Safety will be reported as the incidence of Treatment Emergent Serious Adverse Events (TE-SAEs) assessed by treating physician

    Time frame: Day 30

07

Study locations

4 sites
08

References and documents

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2021 (actual). Primary completion is estimated for Apr 2027, 71 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 15, 2020
First posted
Jul 20, 2020
StartActual
May 7, 2021
Primary completionEst.
Apr 2027
CompletionEst.
Apr 2027
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Sep 29, 2026
Enrollment
136 (estimated)→107 (actual)
Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    Recruiting→Active, not recruiting
    Enrollment 136 (estimated)→107 (actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04476901
Lead sponsor
Joshua M Hare
Collaborators
United States Department of Defense, The University of Texas Health Science Center, Houston
Responsible party
Joshua M Hare (Principal Investigator, University of Miami) — Sponsor-investigator
First posted
Jul 20, 2020
Start date
May 7, 2021
Primary completion
Apr 2027 (estimated)
Completion
Apr 2027 (estimated)
Last update
Sep 29, 2026

Study contacts

Joshua Hare, MD
principal investigator · University of Miami

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion